Factor XIa and tissue factor activity in patients with coronary artery disease
Saulius Butenas1, Anetta Undas2, Matthew T. Gissel1, Konstanty Szuldrzynski3, Krzysztof Zmudka2, Kenneth G. Mann1
1University of Vermont, Department of Biochemistry, Burlington, Vermont, USA; 2Institute of Cardiology and 3Department of Medicine, Jagiellonian University School of Medicine, Krakow, Poland
Coronary artery disease, Tissue factor, factor XIa, inflammation markers, coagulation markers
It has been established that inflammation and enhanced procoagulant activity are associated with the pathogenesis of atherosclerotic vascular disease. We evaluated and compared the contributions of the factor (F)XIa and tissue factor (TF) activity in plasma of patients with coronary artery disease (CAD). Citrate plasma was obtained prior to therapy from 53 patients with stable angina (29 with a history of previous myocardial infarction; CAD-MI) and 30 with acute coronary syndrome (ACS) within 12 hours from pain onset. Four ACS patients treated with heparin were excluded. FXIa andTF activity were determined in clotting assays based upon the prolongation of clotting time by inhibitory monoclonal antibodies.Twenty-five of 26ACS patients (96%) and 22 of 29 CAD-MI patients (76%) had quantifiable FXIa (50 ± 33 and 42 ± 45pM, respectively).Ten of 26 (38%) ACS patients and only three of 53 (6%) stable CAD patients showedTF activity (<0.4pM). No FXIa or TF activity was observed in agematched healthy controls (n=12).For both CAD-MI andACS patients, there were correlations (p<0.05) between FXIa and interleukin- 6 (R2= 0.59 and 0.39, respectively) and between FXIa and TAT (R2= 0.64 and 0.63, respectively). In conclusion, the majority of ACS and CAD-MI patients have circulating FXIa that correlates with markers of coagulation and inflammation.